

BIOCON GROUP

FACT SHEET

December - 2015

IN RUPEES MILLION

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET	(Rs. Million)	
	Dec 31, 2015	March 31, 2015
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	1,000	1,000
(b) Reserves and surplus	36,413	31,706
	37,413	32,706
Minority interest	3,261	1,722
Non-current liabilities		
(a) Long-term borrowings	9,426	7,696
(b) Deferred tax liability (net)	348	417
(c) Other long-term liabilities	5,481	5,516
(d) Long-term provisions	216	150
	15,471	13,779
Current liabilities		
(a) Short-term borrowings	2,542	2,609
(b) Trade payables	5,232	4,293
(c) Other current liabilities	5,585	7,062
(d) Short-term provisions	942	1,582
	14,301	15,546
TOTAL	70,446	63,753
ASSETS		
Non-current assets		
(a) Fixed assets	36,784	32,800
(b) Good will	344	264
(c) Long term loans and advances	3,676	3,693
(d) Other non-current assets	3,375	1,370
	44,179	38,127
Current assets		
(a) Current Investments	3,653	2,303
(b) Inventories	5,326	4,527
(c) Trade receivables	7,254	7,705
(d) Cash and cash equivalents	7,136	9,375
(e) Short term loans and advances	1,253	758
(f) Other current assets	1,645	958
	26,267	25,626
TOTAL	70,446	63,753

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Million)

Particulars	9M FY 16	9M FY 15	Variance
INCOME			
Biopharmaceuticals	17,364	16,449	6%
Biopharma *	14,007	13,137	7%
Branded formulations - India	3,357	3,312	1%
Contract research	7,444	5,841	27%
Total Sales	24,808	22,290	11%
Other income	896	593	51%
TOTAL REVENUE	25,704	22,883	12%
EXPENDITURE			
Material & Power costs	10,838	10,458	4%
Staff costs	4,237	3,674	15%
Research & Development **	1,752	1,128	55%
Other expenses	2,210	2,140	3%
Manufacturing, staff & other expenses	19,037	17,400	
EBITDA	6,667	5,483	22%
Interest & Finance charges	88	104	-15%
Depreciation & Amortisation	1,795	1,624	11%
PBT BEFORE EXCEPTIONAL ITEM	4,784	3,755	27%
Exceptional item, Net	3,070	-	
PBT BEFORE EXCEPTIONAL ITEM	7,854	3,755	109%
Taxes	945	638	
Taxes on exceptional item	1,042	-	
NET PROFIT BEFORE MINORITY INTEREST	5,867	3,117	88%
Minority interest	515	158	
NET PROFIT FOR THE PERIOD	5,352	2,959	81%
EPS Rs.	26.8	14.8	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	528	383	
** Gross Research & Development expenses	2,746	2,291	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Million)
Particulars	Q3 FY 16	Q2 FY 16	Variance
INCOME			
Biopharmaceuticals	5,581	5,778	-3%
Biopharma *	4,536	4,588	-1%
Branded formulations - India	1,045	1,190	-12%
Contract research	2,701	2,504	8%
Total Sales	8,282	8,282	0%
Other income	289	336	-14%
TOTAL REVENUE	8,571	8,618	-1%
EXPENDITURE			
Material & Power costs	3,537	3,685	-4%
Staff costs	1,458	1,367	7%
Research & Development **	679	574	18%
Other expenses	809	770	5%
Manufacturing, staff & other expenses	6,483	6,396	
EBITDA	2,088	2,222	-6%
Interest & Finance charges	15	29	-48%
Depreciation & Amortisation	621	596	4%
PBT BEFORE EXCEPTIONAL ITEM	1,452	1,597	-9%
Exceptional item, net	-	3,070	
PBT	1,452	4,667	-69%
Taxes	241	336	
Taxes on exceptional item	-	1,042	
NET PROFIT BEFORE MINORITY INTEREST	1,211	3,289	-63%
Minority interest	181	230	
NET PROFIT FOR THE PERIOD	1,030	3,059	-66%
EPS Rs.	5.2	15.3	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	320	16	
** Gross Research & Development expenses	912	905	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Million)
Particulars	Q3 FY 16	Q3 FY 15	Variance
<u>INCOME</u>			
Biopharmaceuticals	5,581	5,413	3%
Biopharma *	4,536	4,366	4%
Branded formulations - India	1,045	1,047	0%
Contract research	2,701	2,196	23%
Total Sales	8,282	7,609	9%
Other income	289	181	60%
TOTAL REVENUE	8,571	7,790	10%
<u>EXPENDITURE</u>			
Material & Power costs	3,537	3,604	-2%
Staff costs	1,458	1,260	16%
Research & Development **	679	467	45%
Other expenses	809	762	6%
Manufacturing, staff & other expenses	6,483	6,093	
EBITDA	2,088	1,697	23%
Interest & Finance charges	15	48	-69%
Depreciation & Amortisation	621	563	10%
PBT BEFORE EXCEPTIONAL ITEM	1,452	1,086	34%
Exceptional item, Net	-	-	
PBT	1,452	1,086	34%
Taxes	241	111	
Taxes on exceptional item	-	-	
NET PROFIT BEFORE MINORITY INTEREST	1,211	975	24%
Minority interest	181	66	
NET PROFIT FOR THE PERIOD	1,030	909	13%
EPS Rs.	5.2	4.6	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	320	100	
** Gross Research & Development expenses	912	850	

BIOCON GROUP

FACT SHEET

December - 2015

IN RUPEES CRORE

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET	(Rs. Crore)	
	Dec 31, 2015	March 31, 2015
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	3,641	3,171
	3,741	3,271
Minority interest	326	172
Non-current liabilities		
(a) Long-term borrowings	943	770
(b) Deferred tax liability (net)	35	42
(c) Other long-term liabilities	548	552
(d) Long-term provisions	22	15
	1,548	1,379
Current liabilities		
(a) Short-term borrowings	254	261
(b) Trade payables	523	429
(c) Other current liabilities	559	706
(d) Short-term provisions	94	157
	1,430	1,553
TOTAL	7,045	6,375
ASSETS		
Non-current assets		
(a) Fixed assets	3,678	3,280
(b) Goodwill	34	26
(c) Long term loans and advances	368	368
(d) Other non-current assets	338	137
	4,418	3,811
Current assets		
(a) Current Investments	365	230
(b) Inventories	533	453
(c) Trade receivables	725	771
(d) Cash and cash equivalents	714	938
(e) Short term loans and advances	125	76
(f) Other current assets	165	96
	2,627	2,564
TOTAL	7,045	6,375

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crore)
Particulars	9M FY 16	9M FY 15	Variance
INCOME			
Biopharmaceuticals	1,736	1,645	6%
Biopharma *	1,400	1,314	7%
Branded formulations - India	336	331	1%
Contract research	744	584	27%
Total Sales	2,480	2,229	11%
Other income	90	59	51%
TOTAL REVENUE	2,570	2,288	12%
EXPENDITURE			
Material & Power costs	1,083	1,046	4%
Staff costs	424	367	15%
Research & Development **	175	113	55%
Other expenses	221	214	3%
Manufacturing, staff & other expenses	1,903	1,740	
EBITDA	667	548	22%
Interest & Finance charges	9	10	-15%
Depreciation & Amortisation	179	162	11%
PBT BEFORE EXCEPTIONAL ITEM	479	376	27%
Exceptional item, Net	307	-	
PBT	786	376	109%
Taxes	95	64	
Taxes on exceptional item	104	-	
NET PROFIT BEFORE MINORITY INTEREST	587	312	88%
Minority interest	52	16	
NET PROFIT FOR THE PERIOD	535	296	81%
EPS Rs.	26.8	14.8	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
* Biopharma Income includes: Licensing Income	53	38	
** Gross Research & Development expenses	275	229	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crore)
Particulars	Q3 FY 16	Q2 FY 16	Variance
INCOME			
Biopharmaceuticals	558	578	-3%
Biopharma *	454	459	-1%
Branded formulations - India	104	119	-12%
Contract research	270	250	8%
Total Sales	828	828	0%
Other income	29	33	-14%
TOTAL REVENUE	857	861	-1%
EXPENDITURE			
Material & Power costs	353	368	-4%
Staff costs	146	137	7%
Research & Development **	68	57	18%
Other expenses	81	77	5%
Manufacturing, staff & other expenses	648	639	
EBITDA	209	222	-6%
Interest & Finance charges	2	2	
Depreciation & Amortisation	62	60	4%
PBT BEFORE EXCEPTIONAL ITEM	145	160	-9%
Exceptional item, net	-	307	
PBT	145	467	-69%
Taxes	24	34	
Taxes on exceptional item	-	104	
NET PROFIT BEFORE MINORITY INTEREST	121	329	-63%
Minority interest	18	23	
NET PROFIT FOR THE PERIOD	103	306	-66%
EPS Rs.	5.2	15.3	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
<i>* Biopharma Income includes:</i>			
Licensing Income	32	2	
<i>** Gross Research & Development expenses</i>			
	91	90	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crore)
Particulars	Q3 FY 16	Q3 FY 15	Variance
<u>INCOME</u>			
Biopharmaceuticals	558	541	3%
Biopharma *	454	436	4%
Branded formulations - India	104	105	0%
Contract research	270	220	23%
Total Sales	828	761	9%
Other income	29	18	60%
TOTAL REVENUE	857	779	10%
<u>EXPENDITURE</u>			
Material & Power costs	353	360	-2%
Staff costs	146	126	16%
Research & Development **	68	47	45%
Other expenses	81	76	6%
Manufacturing, staff & other expenses	648	609	
EBITDA	209	170	23%
Interest & Finance charges	2	5	
Depreciation & Amortisation	62	56	10%
PBT BEFORE EXCEPTIONAL ITEM	145	109	34%
Exceptional item, Net	-	-	
PBT	145	109	34%
Taxes	24	11	
Taxes on exceptional item	-	-	
NET PROFIT BEFORE MINORITY INTEREST	121	98	24%
Minority interest	18	7	
NET PROFIT FOR THE PERIOD	103	91	13%
EPS Rs.	5.2	4.6	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	32	10	
** Gross Research & Development expenses	91	85	